FY2029 EPS Forecast for Kura Oncology Decreased by Analyst

Key Points

• Brookline Capital Markets lowered its FY2029 EPS forecast for Kura Oncology to $5.59 from $5.70 and projected FY2030 EPS of $17.45.
• Kura reported a quarterly loss of $0.78 per share, better than the $0.82 loss analysts expected, while revenue of $22.84 million fell short of the $24.94 million consensus.
• Analyst sentiment remains positive overall: MarketBeat reported a “Moderate Buy” consensus rating and an average price target of $25.35.

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities research analysts at Brookline Capital Markets dropped their FY2029 earnings per share estimates for Kura Oncology in a research report issued on Tuesday, November 10th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn $5.59 per share for the year, down from their prior forecast of $5.70. The consensus estimate for Kura Oncology's current full-year earnings is ($3.25) per share. Brookline Capital Markets also issued estimates for Kura Oncology's FY2030 earnings at $17.45 EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 265.89% and a negative net margin of 369.26%. The company had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million.

A number of other analysts have also commented on KURA. Barclays set a $24.00 price target on shares of Kura Oncology in a research note on Wednesday, October 14th. Wedbush raised their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Thursday, August 13th. UBS Group restated a "buy" rating on shares of Kura Oncology in a report on Monday, October 5th. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday, August 24th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and a consensus price target of $25.35.

Kura Oncology Stock Performance

KURA opened at $7.73 on Thursday. The company's 50-day simple moving average is $10.39 and its two-hundred day simple moving average is $9.78. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. Kura Oncology has a 52-week low of $6.75 and a 52-week high of $13.90.

Insider Activity at Kura Oncology

In related news, insider Brian Powl sold 15,430 shares of the business's stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $165,872.50. Following the transaction, the insider directly owned 136,819 shares of the company's stock, valued at approximately $1,470,804.25. The trade was a 10.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Teresa Bair sold 8,442 shares of the company's stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $10.50, for a total value of $88,641.00. Following the completion of the transaction, the insider owned 187,002 shares of the company's stock, valued at $1,963,521. The trade was a 4.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 153,881 shares of company stock worth $1,708,183 in the last three months. Corporate insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. IFP Advisors Inc boosted its position in shares of Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company's stock worth $28,000 after acquiring an additional 1,467 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Kura Oncology by 14.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company's stock valued at $175,000 after acquiring an additional 2,104 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Kura Oncology by 11.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company's stock valued at $194,000 after acquiring an additional 2,304 shares during the last quarter. Sterling Capital Management LLC lifted its stake in Kura Oncology by 842.5% in the 3rd quarter. Sterling Capital Management LLC now owns 2,818 shares of the company's stock worth $30,000 after purchasing an additional 2,519 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Kura Oncology by 22.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company's stock worth $154,000 after purchasing an additional 2,656 shares in the last quarter.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company's best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.